Abstracts tagged "Epidemiology"

Abstract Number: 1753 • ACR Convergence 2022
Temporal Trends of SLE Mortality Among Various Ethnic Categories Across the United States: 2001-to 2020 Analysis from WONDER Database
Ikwinder Preet Kaur¹, Harjot Jagdey², hasan Mirza³, Waqar Mughal⁴ and Pankaj Bansal⁵, ¹Rutgers/Monmouth Medical Center, Long branch, NJ, ²BronxCare Hospital, Bronx, NY, ³Berkshire Medical Center, Pittsfield, MA, ⁴DHQ teaching hospital, Gujrat, Pakistan, ⁵Mayo Clinic, Eau Claire, WI
Background/Purpose: Racial disparities in SLE have been well described. Blacks are disproportionately affected, and have a higher incidence, disease severity, and mortality compared to Whites,…
Abstract Number: 1921 • ACR Convergence 2022
Association Between Knee Osteoarthritis and Health-Related Quality of Life in Persons with Type 2 Diabetes
Lauren King¹, Esther Waugh¹, Ian Stanaitis², Alanna Weisman¹, Baiju Shah¹, Lorraine Lipscombe¹ and Gillian Hawker¹, ¹University of Toronto, Toronto, ON, Canada, ²Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Knee osteoarthritis (OA) and type 2 diabetes commonly co-occur due to shared risk factors. Both knee OA and type 2 diabetes negatively impact health-related…
Abstract Number: L04 • ACR Convergence 2021
SARS-CoV-2 Infections Among Vaccinated Individuals with Rheumatic Disease: Results from the COVID-19 Global Rheumatology Alliance Provider Registry
Jean Liew¹, milena Gianfrancesco², Carly Harrison³, zara Izadi², Stephanie Rush², Lindsay Jacobsohn², Clairissa Ja², Saskia Lawson-Tovey⁴, Kimme Hyrich⁵, Laure Gossec⁶, Anja Strangfeld⁷, Loreto Carmona⁸, Martin Schaefer⁷, ELSA MATEUS⁹, Samar Al Emadi¹⁰, Claire Cook¹¹, Fatemah Abutiban¹², Dfiza Dey¹³, Emily Kowalski¹⁴, Marco Martinez-Martinez¹⁵, Naomi Patel¹¹, Evelyn Salido¹⁶, Jeffrey Sparks¹⁷, leanna Wise¹⁸, Suleman Bhana¹⁹, Wendy Costello²⁰, Rebecca Grainger²¹, Jonathan Hausmann²², Emily Sirotich²³, Paul Sufka²⁴, Zachary Wallace²⁵, Pedro Machado²⁶, Philip Robinson²⁷ and Jinoos Yazdany², ¹Boston University School of Medicine, Boston, MA, ²University of California San Francisco, San Francisco, CA, ³Lupus Chat, New York, NY, ⁴Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Universite, Paris, France APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France, Paris, France, ⁷German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany, ⁸Instituto de Salud Musculoesquelética, Madrid, Spain, ⁹EULAR, Lisboa, Portugal, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Massachusetts General Hospital, Boston, MA, ¹²Rheumatology Unit, Department of Medicine, Jaber Alahmed Alsabah Hospital, KUWAIT, Kuwait, ¹³Rheumatology Unit , Department of Medicine and Therapeutics, University of Ghana Medical School, Korle Bu Teaching Hospital, Accra, Ghana, ¹⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹⁵Instituto Mexicano del Seguro Social, San Luis Potosí, Mexico, ¹⁶University of the Philippines Manila, Manila, Philippines, ¹⁷Brigham and Women's Hospital, Boston, MA, ¹⁸University of Southern California, Los Angeles, CA, ¹⁹Pfizer, Montvale, NJ, ²⁰Irish Children's Arthritis Network (iCAN), Bansha, Ireland, ²¹University of Otago, Wellington, New Zealand, ²²Boston Childrens Hospital, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²³McMaster University, Hamilton, ON, Canada, ²⁴HealthPartners, Eagan, MN, ²⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²⁶Centre for Rheumatology & Department of Neuromuscular Diseases, University College London; National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, University College London Hospitals NHS Foundation Trust; Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, London, United Kingdom, ²⁷University of Queensland School of Clinical Medicine, Herston, Queensland; Department of Rheumatology, Royal Brisbane and Women’s Hospital, Metro North Hospital and Health Service, Queensland, Australia., Brisbane, Australia
Background/Purpose: While COVID-19 vaccinations are a critical tool to prevent severe infections, poor immunogenicity in immunocompromised people threatens vaccine effectiveness. We analyzed clinical characteristics of…
Abstract Number: L17 • ACR Convergence 2021
Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients Without SARS-CoV-2 Antibody Seroconversion After Primary mRNA Vaccination: A Randomized Controlled Trial
Michael Bonelli¹, Daniel Mrak¹, Selma Tobudic¹, Daniela sieghart¹, Peter Mandl¹, barbara kornek¹, elisabeth simader¹, Maximilian Koblischke¹, Helga Radner¹, thomas perkmann¹, helmuth haslacher¹, Margareta Mayer¹, philipp hofer¹, Kurt Redlich², Emma Husar-Memmer³, Ruth Fritsch-Stork⁴, Renate Thalhammer¹, Karin Stiasny¹, Stefan Winkler¹, Josef Smolen¹, Judith Aberle¹, Markus Zeitlinger¹, Leonhard Heinz¹ and Daniel Aletaha⁵, ¹Medical University of Vienna, Vienna, Austria, ²Hietzing Hospital, Vienna, Austria, ³Hanusch Hospital, Vienna, Austria, ⁴Sigmund Freud University, Utrecht, Netherlands, ⁵Medical University Vienna, Wien, Austria
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed patients, who inadequately respond to…
Abstract Number: 0094 • ACR Convergence 2021
Characteristics Associated with Severe Outcomes in Patients with Systemic Rheumatic Diseases Hospitalized for COVID-19 in New York City
Caroline Siegel¹, Jacky Choi², Debra D'Angelo², Paul Christos², Lindsay Lally¹, Parag Goyal², Lisa Mandl¹ and Medha Barbhaiya¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Patients with systemic rheumatic diseases (SRD) are potentially at increased risk of severe outcomes from SARS-CoV-2 infection due to their underlying immune dysregulation and…
Abstract Number: 0368 • ACR Convergence 2021
Geographical Prevalence of Family History in Patients with Axial SpA and Its Association with HLA-B27: Data from the Worldwide ASAS-perSpA Study
Miranda van Lunteren¹, Anne Boel¹, Clementina López Medina², Joachim Sieper³, Désirée van der Heijde⁴ and Floris van Gaalen¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands
Background/Purpose: Research has shown that in patients with axial spondyloarthritis (axSpA), the most common form of spondyloarthritis (SpA) in a family history is axSpA. Moreover,…
Abstract Number: 0571 • ACR Convergence 2021
The National Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2014-2016
Sofia Exarchou¹, Daniela Di Giuseppe², Gerd-Marie Alenius³, Eva Klingberg⁴, Valgerdur Sigurdardottir⁵, Sara Wedrén⁶, Ulf Lindström⁷, Carl Turesson⁸, Lennart Jacobsson⁷, Johan Askling² and Johan Karlsson Wallman⁹, ¹Lund University, Malmö, Sweden, ²Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ³Umeå University, Umeå, Sweden, Umeå, Sweden, ⁴University of Gothenburg, Gothenburg, Sweden and Sahlgrenska University Hospital, Gothenburg, Sweden, ⁵Uppsala University, Uppsala, Sweden and Falun Hospital, Falun, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁷University of Gothenburg, Gothenburg, Sweden, ⁸Lund University, Malm, Sweden, ⁹Lund University and Skane University Hospital, Hjarup, Sweden
Background/Purpose: Psoriatic arthritis (PsA) incidence estimates vary considerably, and nationwide estimates are sparse. In Sweden, PsA is typically diagnosed in specialized care, although a limited…
Abstract Number: 0768 • ACR Convergence 2021
Poverty and Length of Stay in Children Hospitalized with Pediatric Systemic Lupus Erythematosus: An Analysis of the 2016 Kids’ Inpatient Database
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: Prior studies have demonstrated alarming health disparities in adult patients with SLE, including higher disease severity and activity among Hispanic and Black patients. Pediatric…
Abstract Number: 1042 • ACR Convergence 2021
Multimorbidity Prevalence in Systemic Lupus Erythematosus: A Population-Based Study
Ali Duarte-Garcia¹, Maria Valenzuela-Almada², Mehmet Hocaoglu³, Jesse Dabit¹, Shirley-Ann Osei-Onomah¹, Sebastian Vallejo-Ramos¹, Kurt Greenlund⁴, Tina Gunderson¹, Kamil Barbour⁴ and Cynthia Crowson⁵, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 3-fold increase in all-cause mortality, compared to the general population. Young patients with SLE are 40…
Abstract Number: 1556 • ACR Convergence 2021
Mortality Rate Related to COVID-19 in Rheumatic and Musculoskeletal Diseases (RMDs)
Ines Perez - Sancristobal¹, Dalifer Freites¹, Leticia Lopez Pedraza², Maria Paula Alvarez Hernandez¹, Jose Ignacio Colomer³, Alfredo Madrid - Garcia², Benjamin Fernandez¹, Cristina Vadillo¹, Luis Rodriguez Rodriguez⁴, Arkaitz Mucientes², Leticia Leon - Mateos² and Lydia Abasolo⁵, ¹Hospital Clínico San Carlos, Reumathology, Madrid, Madrid, Spain, ²Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Reumathology, Madrid, Spain, ³Fundación para la Investigación Biomedica, Reumathology, Madrid, Spain, ⁴Hospital Clinico San Carlos, Madrid, Spain, ⁵Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In patients with rheumatic and musculoskeletal diseases (RMDs) and infected with Covid – 19, a) we want to assess the mortality rate (MR) related…
Abstract Number: 0096 • ACR Convergence 2021
The True Prevalence of SARS-CoV-2 Infection in an Italian Cohort of Patients with Inflammatory Arthritis: A Seroepidemiological Study
Gabriella Maioli¹, Ennio Giulio Favalli², Elisa Pesce³, Martina Biggioggero², Mauro Bombaci³, Elena Agape², Martina Martinovic³, Tanya Fabbris³, Elena Zagato³, Andrea Favalli³, Andrea Gobbini³, Sergio Abrignani³, Renata Grifantini³ and Roberto Caporali⁴, ¹Università degli Studi di Milano, Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Milan, Italy, Milan, Italy, ²ASST Gaetano Pini-CTO Institute, Division of Clinical Rheumatology, Milan, Italy, Milan, Italy, ³Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy, ⁴Policlinico S. Matteo University, Pavia, Italy
Background/Purpose: Observational data have shown that rheumatic patients seem not to be more susceptible to SARS-CoV-2 infection neither to worse outcomes. However, the true prevalence…
Abstract Number: 0377 • ACR Convergence 2021
The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands
Stan Kieskamp, Suzanne Arends, Elisabeth Brouwer, Hendrika Bootsma, Ilja Nolte and Anneke Spoorenberg, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Chronic low back pain (CLBP; back pain >3 months) with onset at age < 45 and inflammatory back pain (IBP) are regarded as early…
Abstract Number: 0574 • ACR Convergence 2021
Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study
Tina Mahajan¹, Daniel Hershberger¹, Matt Devries², Punyasha Roul¹, Yangyuna Yang¹, Sherrie Edwards¹, Geoffrey Thiele¹, Ted Mikuls¹, James O'Dell¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha
Background/Purpose: Several types of lung diseases complicate the rheumatoid arthritis (RA) disease course such as interstitial lung disease (ILD) and obstructive lung diseases. The prevalence…
Abstract Number: 0795 • ACR Convergence 2021
Treatment Response and Several Patient-reported Outcomes Are Early Determinants of Future Self-efficacy in Patients with Rheumatoid Arthritis
Michal Doumen¹, Diederik De Cock¹, Sofia Pazmino¹, Delphine Bertrand¹, Rene Westhovens² and Patrick Verschueren³, ¹KU Leuven, Leuven, Belgium, ²University Hospitals KU Leuven, Maaseik, Belgium, ³University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: Self-efficacy (SE), or patients’ confidence in their ability to control disease and its consequences, was recently prioritised in EULAR-recommendations for self-management strategies for inflammatory…
Abstract Number: 1046 • ACR Convergence 2021
Risk of Ocular Comorbidities and Blindness Among Patients with Behçet’s Disease: A Nationwide Population-based Cohort Study in Korea
SE RIM CHOI¹, Anna Shin², Joo Young Shin³, Hokyung Choung³, You-Jung Ha², Yun Jong Lee⁴, Eun bong Lee¹, Jin Kyun Park¹ and Eun Ha Kang², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Department of Ophthalmology, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, ⁴Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
Background/Purpose: To examine the risk of ocular comorbidities in a nation-wide cohort of patients with Behçet’s disease (BD) compared to general population in Korea.Methods: We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].